Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.57 |
| ▸ | FAAH | O00519 | 2/20 | 0.57 |
| ▸ | GSK3A | P49840 | 3/20 | 0.49 |
| ▸ | GSK3B | P49841 | 3/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.36 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5072436 | 0.84 | MGLL (0.63) | MGLLFAAHGSK3AGSK3BPTGS1 | |
| SCHEMBL28752497 | 0.82 | MGLL (0.61) | MGLLFAAHGSK3AGSK3BPTGS1 | |
| SCHEMBL32665316 | 0.76 | MGLL (0.57) | MGLLFAAHGSK3AGSK3BPTGS1 | |
| SCHEMBL146412 | 0.74 | MGLL (1.00) | MGLLFAAHGSK3AGSK3BPTGS1 | |
| SCHEMBL4804503 | 0.74 | MGLL (0.78) | MGLLFAAHGSK3AGSK3BPTGS1 | |
| SCHEMBL6339922 | 0.73 | COMT (0.42) | MGLLFAAHGSK3AGSK3BPTGS1 | |
| SCHEMBL7224603 | 0.71 | MGLL (0.60) | MGLLFAAHGSK3AGSK3BPTGS1 | |
| SCHEMBL140975 | 0.71 | MGLL (0.72) | MGLLFAAHGSK3AGSK3BPTGS1 | |
| SCHEMBL11268814 | 0.70 | HRH3 (0.53) | — | |
| SCHEMBL12784728 | 0.69 | MGLL (0.63) | MGLLFAAHGSK3AGSK3BPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903114-B2 | Derivatives of naphthalene with COMT inhibiting activity | ORION CORPORATION (FI) | 2005-06-07 | — | — | US | disclosed |
| US-20040034011-A1 | Derivatives of naphthalene with comt inhibiting activity | ORION CORPORATION (FI) | 2004-02-19 | — | — | US | disclosed |
| EP-1317411-A1 | DERIVATIVES OF NAPHTHALENE WITH COMT INHIBITING ACTIVITY | ORION CORPORATION (FI) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002022551-A1 | DERIVATIVES OF NAPHTHALENE WITH COMT INHIBITING ACTIVITY | ORION CORPORATION (FI) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034011-A1 | Derivatives of naphthalene with comt inhibiting activity | COMT, CYP1A1, CYP1B1 | MGLL 3134/4885FAAH 1356/4885GSK3A 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.